Menu
Close
Global
×

Company News

Company News
Company News
2026-08-07
ImmuneOnco Subsidiary ImmuneCare Completes Multi-Million Yuan Strategic Capital Increase to Accelerate Non-Oncology Pipeline Development
This capital increase aims to further strengthen ImmuneCare's financial resources and accelerate the research and development of innovative drugs in cardiovascular diseases, such as pulmonary arterial hypertension (PAH), as well as metabolic diseases. This marks the steady implementation of ImmuneOnco's "oncology + non-oncology" dual-engine strategy.
View more
2026-07-27
ImmuneOnco Successfully Convenes Phase II Investigator Meeting of IMC-002 (IMM0306) for Active Systemic Lupus Erythematosus (SLE）
The event aimed to provide a comprehensive overview of the study protocol and unify trial execution standards, laying a solid foundation for the clinical study that is now fully underway.
View more
2026-07-21
IMM2510S，the Subcutaneous Formulation of IMM2510 Completes First Patient Dosing in Phase I Clinical Study, Ushering in a New Era of Convenient Dual-Target Therapy
This milestone is expected to provide a novel treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.
View more
2026-07-16
ImmuneOnco Completes planned Enrollment of 173 Patients in Phase III Registrational Trial of Timdarpacept (IMM01) for CMML
Previously, the study met its pre-specified interim analysis enrollment target of 132 patients ahead of schedule in March 2026 (with an actual enrollment of 133 patients), and completed the full enrollment of 173 patients in June 2026.
View more
2026-07-10
Amulirafusp Alfa (IMM0306): Phase II/III Clinical Study for IgG4-RD Successfully Completes First Patient Dosing
This significant milestone marks the official commencement of the clinical development of this innovative drug in the field of rare autoimmune diseases, bringing new therapeutic hope to IgG4-RD patients who face substantial unmet medical needs.
View more
2026-07-02
ImmuneOnco Announces NMPA Approval of IND Application for IMM2510S Subcutaneous Formulation, Further Validating the Clinical Potential of Its Dual-Targeting Therapy
This milestone marks a significant step in providing patients with advanced solid tumors a more convenient and safer treatment option through optimized drug delivery.
View more
总计 110 12345678...1819